Promising Anatomic Outcomes from LIGHTSITE III Trial

Diana V. Do, MD, and Glenn J. Jaffe, MD

Show Description +

Diana V. Do, MD, and Glenn J. Jaffe, MD, discuss key anatomic findings from the LIGHTSITE III clinical trial evaluating photobiomodulation (PBM) with the FDA-authorized Valeda® Light Delivery System (LumiThera, Inc.) to treat dry age-related macular degeneration (AMD). Drs. Do and Jaffe share their observations of the data, citing a decrease in the proportion of eyes that developed geographic atrophy and a reduction of drusen volume.

Posted: 5/16/2025

Keywords:

LumiThera

•

Valeda

•

Photobiomodulation

•

Clinical Trials

•

Age-Related Macular Degeneration (AMD)

•

drusen

•

Geographic Atrophy (GA)

Up Next

Valeda Demonstrates Vision Improvement in Patients with Dry AMD

Diana V. Do, MD, and Glenn J. Jaffe, MD

Safety and Efficacy Results from LIGHTSITE III Trial for Dry AMD

David S. Boyer, MD; and Marion R. Munk, MD, PhD

Valeda Mechanisms of Action – U.S.

Month 24 Clinical Trial Results in Dry AMD Patients

Eleanora Lad, MD, PhD; and Victor Gonzalez, MD

Back to All Videos

Promising Anatomic Outcomes from LIGHTSITE III Trial

Diana V. Do, MD, and Glenn J. Jaffe, MD

Diana V. Do, MD, and Glenn J. Jaffe, MD, discuss key anatomic findings from the LIGHTSITE III clinical trial evaluating photobiomodulation (PBM) with the FDA-authorized Valeda® Light Delivery System (LumiThera, Inc.) to treat dry age-related macular degeneration (AMD). Drs. Do and Jaffe share their observations of the data, citing a decrease in the proportion of eyes that developed geographic atrophy and a reduction of drusen volume.

Posted: 5/16/2025

Keywords:

LumiThera

•

Valeda

•

Photobiomodulation

•

Clinical Trials

•

Age-Related Macular Degeneration (AMD)

•

drusen

•

Geographic Atrophy (GA)

About LumiThera

Visit Us Online: lumithera.com

Get a Quote | Have Someone Contact Me

Follow LumiThera